StockNews.com initiated coverage on shares of Ayala Pharmaceuticals (OTCMKTS:ADXS – Get Free Report) in a research note issued on Thursday. The brokerage set a “sell” rating on the biotechnology company’s stock.
Separately, LADENBURG THALM/SH SH raised Ayala Pharmaceuticals from a “neutral” rating to a “buy” rating in a research note on Tuesday, May 30th.
Ayala Pharmaceuticals Stock Performance
Shares of ADXS opened at $1.38 on Thursday. The stock has a market capitalization of $2.51 million, a PE ratio of -0.15 and a beta of 2.35. Ayala Pharmaceuticals has a 1 year low of $0.65 and a 1 year high of $4.40. The company’s 50-day simple moving average is $0.96 and its 200-day simple moving average is $1.04.
About Ayala Pharmaceuticals
Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. It is also developing proprietary Lm-based antigen delivery products for patients suffering from common cancers.
Further Reading
- Five stocks we like better than Ayala Pharmaceuticals
- U.S. Bancorp Shares Rally As Analysts Get Bullish After Q2 Report
- AutoNation Beats Earnings Expectations, Stock Down?
- American Express Hiccups After Earnings, Time To Buy?
- ISRG Stock Sinks After Strong Earnings: Is the Growth Priced In?
- Winners And Losers In The Oilfield Supercycle
Receive News & Ratings for Ayala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ayala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
